Physician profile
Alexander Pang
NPI 1497898316
$6,468.16
in general payments reported to CMS, 2019-2025
42 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $234 · 2021: $870 · 2022: $1,232 · 2023: $1,371 · 2024: $1,744 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.37 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $739.22 | 2019-2024 | Xtandi, Myrbetriq |
| Antares Pharma, INC. | $687.87 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $664.49 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $601.89 | 2019-2025 | |
| Janssen Biotech, INC. | $405.95 | 2019-2025 | Erleada, Akeega, Carvykti |
| Telix Pharmaceuticals | $399.86 | 2023-2025 | Illuccix |
| Myriad Genetic Laboratories, INC. | $345.50 | 2021-2023 | Myrisk, Prolaris |
| Abbvie INC. | $293.77 | 2019-2024 | |
| Teleflex LLC | $266.98 | 2021-2024 | Urolift |
| Boston Scientific Corporation | $190.99 | 2019-2023 | Rezum Generator |
| Acerus Pharmaceuticals Corporation | $141.36 | 2022 | |
| Medtronic, INC. | $139.06 | 2024 | Corevalve Evolut R |
| Xeris Pharmaceuticals, INC. | $120.66 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $120.43 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $119.24 | 2021-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $114.67 | 2022-2024 | Jardiance, Zepbound |
| Endo Pharmaceuticals INC. | $109.25 | 2019-2024 | Xiaflex, Aveed |
| Abbott Laboratories | $108.07 | 2019-2020 | |
| Dentsply Ih Ab | $106.30 | 2023-2024 | Lofric, Lofric |
| Merck Sharp & Dohme LLC | $99.44 | 2019-2024 | Keytruda |
| Urovant Sciences INC | $66.98 | 2022 | |
| Tolmar, INC. | $56.27 | 2023-2024 | |
| Dentsply Ih INC. | $56.10 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $50.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $45.71 | 2020-2021 | |
| Halozyme INC | $45.29 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $39.19 | 2020-2021 | |
| Corcept Therapeutics | $38.96 | 2019-2023 | Korlym |
| Progenics Pharmaceuticals, INC. | $38.10 | 2024 | |
| Glaxosmithkline, LLC. | $29.78 | 2020 | |
| Endo USA, INC. | $24.47 | 2024 | Aveed, Xiaflex |
| Tempus Ai, INC | $24.01 | 2024 | Xt Cdx |
| Mannkind Corporation | $23.00 | 2023 | Afrezza |
| Olympus America INC. | $22.83 | 2025 | Itind System |
| Alexion Pharmaceuticals, INC. | $19.99 | 2022 | |
| Amgen INC. | $17.52 | 2019 | |
| Dexcom, INC. | $17.28 | 2023 | Dexcom G6 Transmitter |
| Blue Earth Diagnostics | $16.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.01 | 2019 | |
| Baudax Bio INC. | $15.82 | 2021 | |
| Metuchen Pharmaceuticals | $14.41 | 2020 | |
| Axonics, INC. | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.